Acebrophylline PCD Pharma Franchise Company

Cafoli Lifecare offers an Acebrophylline PCD pharma franchise to distributors and stockists building a respiratory portfolio. Our Acebrophylline range is one of our deepest, with 14 formulations across tablets, capsules and syrup, marketed largely under the Abrostep brand. All products are manufactured at WHO-GMP certified facilities and supplied with monopoly distribution rights.

What is Acebrophylline?

Acebrophylline is a dual-acting respiratory agent formed as a salt of ambroxol and theophylline-7-acetic acid, and it is best understood as a mucoregulator combined with a bronchodilator. The ambroxol component stimulates surfactant production and reduces the viscosity of bronchial secretions so that mucus is cleared more easily, while the theophylline-acetate component contributes bronchodilator and anti-inflammatory activity, including suppression of inflammatory mediators in the airway. This combined action on both mucus and bronchial tone is what distinguishes it from a plain bronchodilator. See PubChem: Acebrophylline for the compound profile.

Acebrophylline Products Available for Franchise

These are featured presentations from a wider range of 14 formulations. Contact our team for the complete Acebrophylline product and price list.

Therapeutic Applications of Acebrophylline

Acebrophylline is prescribed in respiratory conditions where bronchial obstruction is accompanied by thick, difficult-to-clear secretions — chronic obstructive pulmonary disease (COPD), bronchial asthma, acute and chronic bronchitis, and bronchitis with a significant mucus component. The fixed-dose combinations extend its use: pairing with montelukast adds leukotriene-receptor blockade for asthma and allergic airway disease, while combinations with desloratadine or bilastine add antihistamine cover where an allergic trigger is present, and the acetylcysteine combinations reinforce the mucolytic effect.

Prescribers are chiefly pulmonologists and chest physicians, general physicians, ENT specialists and paediatricians. Dose and choice of combination are matters for the treating clinician.

Why Acebrophylline is a High-Potential Molecule for Distributors

The respiratory segment is one of the largest and most durable in the Indian market, and the drivers behind it — urban air pollution, high smoking prevalence and a substantial COPD and asthma burden — are not going away. What makes acebrophylline particularly workable for a franchise partner is the breadth of the range rather than any single SKU: with 14 formulations spanning plain capsules, syrup for paediatric and elderly patients, and multiple fixed-dose combinations with montelukast, bilastine, desloratadine and acetylcysteine, a distributor can service a chest physician, a GP and a paediatrician from the same molecule line. Respiratory prescribing also has a seasonal spike in winter and pollution months layered on top of chronic year-round COPD maintenance therapy, which means both a steady base and a predictable peak.

Why Choose Cafoli Lifecare

Cafoli Lifecare grants monopoly distribution rights by district or territory, manufactures at WHO-GMP certified units and supplies DCGI-approved products. Partners receive complete promotional inputs — visual aids, product cards, samples, MR bags and prescription pads — with transparent pricing and reliable dispatch. More than 1000+ franchise partners across India already distribute with us.

References

1. PubChem Compound Summary – Acebrophylline
2. PubMed – Acebrophylline in COPD and airway disease
3. MedlinePlus – COPD